An Is­raeli biotech is look­ing to make its name in the jam-packed CD47 space. Is bi­func­tion­al­i­ty the an­swer?

Jerusalem’s KAHR Med­ical had been work­ing on fu­sion pro­teins for au­toim­mune dis­or­ders for about 10 years, be­fore “is­sues in de­vel­op­ment” spurred then-new CEO Yaron Pereg to change gears in 2017.

“We had done our gap analy­sis and thought, ‘This is a very cool tech­nol­o­gy and very in­ter­est­ing plat­form, why won’t we start from scratch, do things dif­fer­ent and al­so se­lect more nov­el tar­gets?’” he said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER